Sonoma Pharmaceuticals, Inc. (SNOA) Stock Score, Valuation & Financial Research
Sonoma Pharmaceuticals, Inc. is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 24/100.
Quick answer for SNOA
Sonoma Pharmaceuticals, Inc. currently has a Wall Street Score of 24/100. The stored market price is $1.29. Its financial score is 38/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Sonoma Pharmaceuticals, Inc. does
Sonoma Pharmaceuticals, Inc. specializes in the creation and distribution of stabilized hypochlorous acid (HOCl) products. These offerings address a diverse range of medical and health needs, including wound management, veterinary care, ocular hygiene, oral health, and various dermatological conditions. The company's market reach extends across the United States, Latin America, Europe, and other international territories. Its comprehensive product line features: Epicyn: an antimicrobial cleanser for facial use. Levicyn: a prescription HOCl-based treatment formulated to ease the burning, itching, and pain associated with numerous dermatological issues. Celacyn gel: a topical HOCl-based prescription product engineered to facilitate efficient healing and management of both new and old scars. SebuDerm: designed to soothe the burning, itching, redness, scaling, and discomfort linked to seborr
SNOA financial snapshot
- Wall Street Score:
- 24/100
- Current price:
- $1.29
- Market capitalization:
- $2.2M
- Revenue:
- $19.5M
- Net income:
- $-3.2M
- Free cash flow:
- $-4.1M
- Cash:
- $2.4M
- Total debt:
- $842K
- EPS:
- -1.89
- Financial score:
- 38/100
- Valuation score:
- 0/100
- Revenue score:
- 39/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $-4.1M, showing cash burn in the current stored period.
- The balance sheet shows $2.4M of cash versus $842K of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 38/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research SNOA
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.